CRISPR Therapeutics rStock

CRISPR Therapeutics AG is a clinical-stage biopharmaceutical pioneer focused on translating revolutionary Nobel Prize-winning CRISPR-Cas9 gene-editing technology into curative medical therapies. The firm's advanced R&D pipeline targets severe hemoglobinopathies (such as sickle cell disease), immuno-oncology cell therapies (CAR-T), and regenerative medicine, with its asset valuation dictated by clinical milestones and FDA approvals.